This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Durand, R.
Right arrow Articles by Deniau, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Durand, R.
Right arrow Articles by Deniau, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1998, p. 2141-2143, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Leishmania infantum: Lack of Parasite Resistance to Amphotericin B in a Clinically Resistant Visceral Leishmaniasis

Remy Durand,1,* Muriel Paul,2 Francine Pratlong,3 Daniele Rivollet,1 Marie-Laure Dubreuil-Lemaire,4 Rene Houin,1 Alain Astier,2 and Michele Deniau1

Laboratoire de Parasitologie1 and Laboratoire de Pharmacotechnie, Service de Pharmacie,2 and Service d'Immunologie Clinique,4 CHU Henri Mondor, 94010 Créteil, and Laboratoire d'Ecologie Médicale et Pathologie Parasitaire, 34090 Montpellier,3 France

Received 17 February 1998/Returned for modification 21 April 1998/Accepted 9 June 1998

Amphotericin B (AmB) has been used as a second-line treatment of visceral leishmaniasis, particularly in human immunodeficiency virus-positive patients. AmB median effective doses (ED50s) were determined on an isolate obtained before any treatment and on a second isolate obtained 4 years later from the same AmB-treated patient. ED50s were similar (0.059 and 0.067 mg/kg of body weight, respectively), demonstrating the first evidence of AmB ED50 stability of Leishmania infantum after a long-term drug exposure. An isoenzymatic study was performed in order to verify that the second isolate originated from the same parasite as the first isolate. The present case report showed that treatment failure was not due to parasite resistance in spite of a prolonged exposure to the drug.

* Corresponding author. Mailing address: Laboratoire de Parasitologie, Faculté de Médecine, 6 rue du Gal Sarrail, 94010 Créteil, France. Phone: 33 1 49 81 36 31. Fax: 33 1 49 81 36 01. E-mail: rjdurand{at}club-internet.fr.

Antimicrobial Agents and Chemotherapy, August 1998, p. 2141-2143, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Croft, S. L., Sundar, S., Fairlamb, A. H. (2006). Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev. 19: 111-126 [Abstract] [Full Text]  
  • Golenser, J., Frankenburg, S., Ehrenfreund, T., Domb, A. J. (1999). Efficacious Treatment of Experimental Leishmaniasis with Amphotericin B-Arabinogalactan Water-Soluble Derivatives. Antimicrob. Agents Chemother. 43: 2209-2214 [Abstract] [Full Text]  
  • Di Giorgio, C., Faraut-Gambarelli, F., Imbert, A., Minodier, P., Gasquet, M., Dumon, H. (1999). Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantumisolates from patients with visceral leishmaniasis. J Antimicrob Chemother 44: 71-76 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»